Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making.

Friedman C, Lyon M, Torphy RJ, Thieu D, Hosokawa P, Gonzalez R, Lewis KD, Medina TM, Rioth MJ, Robinson WA, Kounalakis N, McCarter MD, Gleisner AL.

J Surg Oncol. 2019 Dec;120(7):1276-1283. doi: 10.1002/jso.25720. Epub 2019 Oct 10.

PMID:
31602665
2.

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.

Hawkins ML, Rioth MJ, Eguchi MM, Cockburn M.

J Am Acad Dermatol. 2019 Jun;80(6):1640-1649. doi: 10.1016/j.jaad.2019.01.009. Epub 2019 Jan 14.

PMID:
30654077
3.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

4.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

5.

Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling.

Rioth MJ, Thota R, Staggs DB, Johnson DB, Warner JL.

J Am Med Inform Assoc. 2016 Jul;23(4):773-6. doi: 10.1093/jamia/ocw002. Epub 2016 Mar 28.

6.

SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care.

Warner JL, Rioth MJ, Mandl KD, Mandel JC, Kreda DA, Kohane IS, Carbone D, Oreto R, Wang L, Zhu S, Yao H, Alterovitz G.

J Am Med Inform Assoc. 2016 Jul;23(4):701-10. doi: 10.1093/jamia/ocw015. Epub 2016 Mar 27.

7.

Implementing and Improving Automated Electronic Tumor Molecular Profiling.

Rioth MJ, Staggs DB, Hackett L, Haberman E, Tod M, Levy M, Warner J.

J Oncol Pract. 2016 Mar;12(3):e332-7. doi: 10.1200/JOP.2015.008276. Epub 2016 Jan 26.

8.

Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology.

Rioth MJ, Warner J, Savani BN, Jagasia M.

Bone Marrow Transplant. 2016 Jan;51(1):34-40. doi: 10.1038/bmt.2015.210. Epub 2015 Sep 14. Review.

9.

Advances in website information resources to aid in clinical practice.

Rioth MJ, Osterman TJ, Warner JL.

Am Soc Clin Oncol Educ Book. 2015:e608-15. doi: 10.14694/EdBook_AM.2015.35.e608. Review.

10.

Immune checkpoint inhibitors in NSCLC.

Johnson DB, Rioth MJ, Horn L.

Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5. Review.

11.

Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.

Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F.

Cancer Cell. 2008 May;13(5):420-31. doi: 10.1016/j.ccr.2008.02.018.

12.

TORC1 is essential for NF1-associated malignancies.

Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K.

Curr Biol. 2008 Jan 8;18(1):56-62. doi: 10.1016/j.cub.2007.11.066. Epub 2007 Dec 27.

13.

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71. Epub 2006 Oct 20.

Supplemental Content

Loading ...
Support Center